Serum OPG levels in myeloma.

(A) Serum OPG levels in patients with myeloma and in healthy controls. OPG in serum samples drawn at diagnosis from 225 patients with multiple myeloma and 40 healthy age- and sex-matched controls was analyzed by ELISA. The median OPG level in patients with myeloma was 7.4 ng/mL (range, 2.6-80) and 9 ng/mL (range, 5.1-130) in controls (P = .02). (B) Serum OPG levels in myeloma grouped by degree of skeletal involvement. Patients were grouped by degree of skeletal involvement of the disease as judged by radiography. Mean OPG levels were 15.5 ng/mL (no lesions), 9.5 ng/mL (one lesion), and 8.3 ng/mL (more than one lesion). Median OPG levels were 9.1 ng/mL (no lesions), 7.6 ng/mL (one lesion), and 7.0 ng/mL (more than one lesion), respectively. Horizontal bars indicate median values. (C) Serum OPG levels in myeloma grouped by WHO performance status. Patients were grouped by WHO performance status. Mean OPG levels were 12 ng/mL (WHO 0), 13.5 ng/mL (WHO 1), 8.0 ng/mL (WHO 2), 8.0 ng/mL (WHO 3), and 7.5 ng/mL (WHO 4). Median OPG levels were 9.3 ng/mL (WHO 0), 9.0 ng/mL (WHO 1), 8.0 ng/mL (WHO 2), 6.8 ng/mL (WHO 3), and 7.0 ng/mL (WHO 4). Horizontal bars indicate median values.